These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 28956259)

  • 1. Checkpoint Inhibitors: Applications for Autoimmunity.
    Tocheva AS; Mor A
    Curr Allergy Asthma Rep; 2017 Sep; 17(10):72. PubMed ID: 28956259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoints and the regulation of tolerogenicity in dendritic cells: Implications for autoimmunity and immunotherapy.
    Funes SC; Manrique de Lara A; Altamirano-Lagos MJ; Mackern-Oberti JP; Escobar-Vera J; Kalergis AM
    Autoimmun Rev; 2019 Apr; 18(4):359-368. PubMed ID: 30738957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer.
    Calabrese LH; Caporali R; Blank CU; Kirk AD
    J Autoimmun; 2020 Dec; 115():102546. PubMed ID: 32980229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival.
    McGonagle D; Bragazzi NL; Amital H; Watad A
    Autoimmun Rev; 2020 Feb; 19(2):102456. PubMed ID: 31838166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity.
    Singh N; Hocking AM; Buckner JH
    Immunol Rev; 2023 Sep; 318(1):81-88. PubMed ID: 37493210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Not All Immune Checkpoints Are Created Equal.
    De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
    Front Immunol; 2018; 9():1909. PubMed ID: 30233564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immune checkpoint inhibitor therapy in advanced head and neck cancer].
    Hang W; Xu ZX; Zhang Q; Lu X; Liu G
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jan; 52(1):67-70. PubMed ID: 28104022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.
    Tsai HF; Hsu PN
    J Biomed Sci; 2017 May; 24(1):35. PubMed ID: 28545567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
    Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
    van der Vlist M; Kuball J; Radstake TR; Meyaard L
    Nat Rev Rheumatol; 2016 Oct; 12(10):593-604. PubMed ID: 27539666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again.
    Bucktrout SL; Bluestone JA; Ramsdell F
    Genome Med; 2018 Oct; 10(1):79. PubMed ID: 30376867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
    Postow MA; Sidlow R; Hellmann MD
    N Engl J Med; 2018 Jan; 378(2):158-168. PubMed ID: 29320654
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy.
    Ebrahimi N; Abdulwahid ARR; Mansouri A; Karimi N; Bostani RJ; Beiranvand S; Adelian S; Khorram R; Vafadar R; Hamblin MR; Aref AR
    Cell Mol Life Sci; 2024 Feb; 81(1):106. PubMed ID: 38418707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7 immune checkpoint family members as putative therapeutics in autoimmune disease: An updated overview.
    Dolatkhah K; Alizadeh N; Mohajjel-Shoja H; Abdoli Shadbad M; Hajiasgharzadeh K; Aghebati-Maleki L; Baghbanzadeh A; Hosseinkhani N; Karim Ahangar N; Baradaran B
    Int J Rheum Dis; 2022 Mar; 25(3):259-271. PubMed ID: 34994525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibition-Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity.
    Thanarajasingam U; Abdel-Wahab N
    Rheum Dis Clin North Am; 2020 Aug; 46(3):587-603. PubMed ID: 32631606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer.
    Bakacs T; Moss RW; Kleef R; Szasz MA; Anderson CC
    Scand J Immunol; 2019 Dec; 90(6):e12821. PubMed ID: 31589347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.